Doubtful as most affected are young males. Sleep aid dude goes over the possibility of compounding factors in young males & the mis-application intravenously being a thing of note.
They want everyone 18 & older to get the J&J booster. Making the point IMO that J&J should have been a two shot regimen to start with. FDA advisers vote unanimously to recommend booster doses of Johnson & Johnson's Covid-19 vaccine https://www.cnn.com/2021/10/15/health/fda-jj-booster-committee-friday/index.html Vaccine advisers to the US Food and Drug Administration voted unanimously Friday to recommend a booster dose of Johnson & Johnson's vaccine at least two months after people get the first dose. The FDA's Vaccines and Related Biological Products Advisory Committee voted 19-0 to recommend the extra dose for all recipients of the J&J Janssen vaccine, 18 and older. They asked to simplify the original question being posed by the FDA, which had asked the committee to say whether the data showed that waiting six months or longer after getting the first shot would provide an even stronger immune response. The FDA will now consider the committee's advice. Then the US Centers for Disease Control and Prevention's vaccine advisers will be asked to consider it. This is a breaking news story and will be updated.
Yes, the recent FDA meeting merely outlined that J&J should have never been rolled out with just one dose. Why the FDA panel's booster greenlight was actually a 'bad meeting' for Johnson & Johnson https://theweek.com/science/1006089/fda-panel-authorize-johnson-johnson-booster-shots An advisory panel for the Food and Drug Administration voted on Friday to recommend authorizing booster shots for Johnson & Johnson's COVID-19 vaccine. The recommendation, which is for people ages 18 and up, suggests boosters at least two months after the initial dose. As some experts view it, the vote essentially changes the Johnson & Johnson vaccine from a "one and done" single dose immunization into something closer to the two-shot regimen created by Moderna and Pfizer. "Many members of the [FDA] panel said that a second dose was important because the first dose did not provide strong enough protection," writes The New York Times. The J&J vaccine has slightly lower efficacy than the other two approved for use in the U.S., but has so far continued to successfully prevent most serious illness or hospitalization among recipients. The panel's vote isn't particularly surprising, since many experts have predicted that boosters would likely be approved to ward against waning immunity, but Stat News' Helen Branswell still reported that "this [turned] out to be a bad meeting for J&J," arguing that it's a bad look for Johnson & Johnson that so many FDA panelists believe the vaccine should become a two-dose regimen. The panel opted to recommend boosters sooner than J&J's suggested 6-month gap between doses. "I think this frankly was always a two-dose vaccine," said panelist Paul Offitt, an infectious disease expert at the Children's Hospital of Philadelphia. "It's hard to recommend this as a one-dose vaccine." Though J&J isn't changing its vaccine authorization to now be considered a two-dose vaccine, that's essentially what the panel thinks it should become. Panelist Eric Rubin, editor-in-chief of The New England Journal of Medicine, said J&J should be asking for a universal booster dose at two months. "He didn't use the term, but that's a two-dose vaccine," writes Branswell. The other aspect of the meeting that doesn't bode well for Johnson & Johnson is that the panel is considering whether to recommend that J&J recipients get a booster from a different company. A vote on that issue will come later. Either way, as health reporters note, the fact that the FDA panel shot down J&J's argument that its COVID-19 vaccine could continue as a single-shot dose with a long gap between the initial jab and an eventual booster is a blow to both the company and Americans who benefited from a "one and done."
Fauci says FDA data shows J&J vaccine should have been two shots https://thehill.com/homenews/admini...vaccine-should-have-likely-been-two-dose-shot
That doesn't look too well for the FDA that had data that J&J needed to be a 2-shot vaccine instead of 1-shot vaccine considering the FDA approved the J&J. This is why I think Covid breakthrough infections for those vaccinated should be documented by each vaccine so that the public can be better aware of which vaccines are performing better than other vaccines. In my opinion, it will help some of those that are vaccine-hesitant to have more data to make a decision to get vaccinated because they will in fact know which vaccine to choose. wrbtrader
Pfizer CEO says he’s gotten a COVID vaccine booster shot and most of us will, too https://www.marketwatch.com/story/p...ster-shot-and-most-of-us-will-too-11634599790
CDC data finds Pfizer vaccine 93 percent effective against hospitalization for youth https://thehill.com/policy/healthca...-93-percent-effective-against-hospitalization The Pfizer-BioNTech COVID-19 vaccine has been found to be 93 percent effective against hospitalization for 12- to 18-year-olds, according to Centers for Disease Control and Prevention (CDC) research from when the delta variant was predominant. Researchers calculated the vaccine efficacy using data from 464 hospitalized patients, including 179 with laboratory-confirmed COVID-19 and 285 controls without the virus, across 19 pediatric hospitals between June and September. The CDC study sought to add to the “limited” real-world data on vaccine effectiveness among 12- to 18-year-olds. It concluded the effectiveness aligned with the results of Pfizer’s previous clinical trial that found a 100 percent efficacy against symptomatic COVID-19 among 12- to 15-year-olds. Out of the 179 COVID-19 patients, only 3 percent were fully vaccinated, while the vast majority had not had any COVID-19 vaccine doses. Patients who were partially vaccinated were excluded from the study. Among the unvaccinated COVID-19 patients, 77 were admitted to the intensive care unit, 29 received life support and two died. None of the six vaccinated COVID-19 patients went to the ICU or received life support care. Almost 60 percent of COVID-19 patients were in the Southern U.S. as the delta strain ravaged the region in the months included in the study, which researchers noted “might limit the representativeness of the sample.” The time span also included when U.S. pediatric COVID-19 hospitalizations reached their highest point during the pandemic in early September amid the delta strain. The study supports previous research showing the effectiveness of the COVID-19 vaccine, including against hospitalizations. Federal health officials have repeatedly said the wide majority of COVID-19 hospitalizations and deaths across the country in recent months involve unvaccinated individuals. Adolescents have the lowest vaccination rates out of the age groups eligible for the vaccine, with 46 percent of 12- to 15-year-olds and 53 percent of 16- to 17-year-olds fully vaccinated, according to the CDC. Those 18 to 24 are not far ahead, with almost 54 percent fully vaccinated. The Food and Drug Administration has not authorized a COVID-19 vaccine for children younger than 12 yet, although an advisory group plans to discuss Pfizer’s application for those 5 to 11 next week.
I was just taking to a director's assistant, a family member of the director, they are usually brighter and he was doing the bla bla about not wanting genetic changes etc. I asked him how viruses replicate and to be fair to the guy, he said he did not know. So explained that a virus hijacks the body's cells which are little factories to produce copies of itself. This results in the death through exhaustion of the modified cell etc. So an mRNA vaccine is doing nothing more than Covid/influenza/others do anyway. I noted how simple current mRNA vs self-amplifying saRNA works etc. The penny dropped with him. It was a remarkable thing to witness. While there are many animations around, I think had they just made a copy of the Jurassic Park Mr DNA animation using the same voice, it would have helped reach many.
This validates why I selected Pfizer for my teenagers when they decided they wanted to get a Covid vaccine. Yet, we had some research help (advice) from a close friend that works at Johns Hopkins. He talked to my kids via conference call with our family doctor and explained each vaccine including the ones not suitable for them (e.g. Moderna) at that particular time. After they became fully vaccinated with Pfizer...the Moderna vaccine was approved for kids < 18 years old here in Canada. Yet, had Moderna been available when we were making the decision about which vaccine...we would have still selected Pfizer for them. In contrast, I selected Moderna. All of us had a complete physical with blood chemistry work before vaccination and again about 30 days after vaccination to ensure there was not any problems like Myocarditis due to the fact I've had Myocarditis twice as a teenager when I was younger / FLU vaccine... No problems. wrbtrader